Payment overview · 2025
General Payments
$409.68
18 reported records · 10 companies
Healthcare provider profile · identity verified
William C Hicok, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BARTONVILLE, IL · NPI 1457326944
Verified facts
What the public records show
CMS Open Payments records show William C Hicok, M.D. received $409.68 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.32 | 25.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.86 | 20.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.77 | 11.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.85 | 9.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.34 | 8.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.10 | 6.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.15 | 5.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.42 | 5.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.32 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.55 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $409.68 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.77 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $38.85 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $35.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.31 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 464 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 108 |
| Lisinopril | Lisinopril | 318 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 88 |
| Omeprazole | Omeprazole | 245 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 60 |
| Gabapentin | Gabapentin | 193 | 59 |
| Tramadol Hcl | Tramadol Hcl | 187 | 46 |
| Furosemide | Furosemide | 182 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 51 |
| Simvastatin | Simvastatin | 174 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 21 |
| Lorazepam | Lorazepam | 139 | 36 |
| Metformin Hcl | Metformin Hcl | 139 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 41 |
| Metformin Hcl Er | Metformin Hcl | 129 | 43 |
| Potassium Chloride | Potassium Chloride | 129 | 43 |
| Glimepiride | Glimepiride | 125 | 32 |
| Losartan Potassium | Losartan Potassium | 121 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 33 |
| Azithromycin | Azithromycin | 117 | 85 |
| Trazodone Hcl | Trazodone Hcl | 113 | 32 |
| Eliquis | Apixaban | 111 | 31 |
| Allopurinol | Allopurinol | 107 | 34 |
| Alprazolam | Alprazolam | 107 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 27 |
| Jardiance | Empagliflozin | 87 | 22 |
| Meloxicam | Meloxicam | 85 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 34 |
| Clonazepam | Clonazepam | 79 | 13 |
| Carvedilol | Carvedilol | 76 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 21 |
| Famotidine | Famotidine | 69 | 22 |
| Montelukast Sodium | Montelukast Sodium | 67 | 24 |
| Cephalexin | Cephalexin | 66 | 40 |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 24 |
| Glipizide Er | Glipizide | 63 | 18 |
| Fenofibrate | Fenofibrate | 61 | 16 |
| Amoxicillin | Amoxicillin | 60 | 31 |
| Sertraline Hcl | Sertraline Hcl | 59 | 18 |
| Methylprednisolone | Methylprednisolone | 55 | 44 |
| Ezetimibe | Ezetimibe | 53 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 12 |
| Buspirone Hcl | Buspirone Hcl | 51 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 35 |
| Celecoxib | Celecoxib | 47 | 18 |
| Meclizine Hcl | Meclizine Hcl | 46 | 18 |
| Ramipril | Ramipril | 46 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Pregabalin | Pregabalin | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | 16 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 12 |
| Atenolol | Atenolol | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Diazepam | Diazepam | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Prednisone | Prednisone | 29 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 15 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 13 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Temazepam | Temazepam | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $409.68 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, COREVALVE EVOLUT R, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, LEQVIO, Ozempic, VOQUEZNA, WATCHMAN Access System, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error